{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T14:50:50Z","timestamp":1742914250009,"version":"3.40.3"},"publisher-location":"New York, NY","reference-count":10,"publisher":"Springer US","isbn-type":[{"type":"print","value":"9781071635407"},{"type":"electronic","value":"9781071635414"}],"license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1007\/978-1-0716-3541-4_7","type":"book-chapter","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:27:05Z","timestamp":1701390425000},"page":"67-77","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Liquid Chromatography-Tandem Mass Spectrometry-Based Therapeutic Monitoring of Plasma Atovaquone Concentrations in Pediatric Patients"],"prefix":"10.1007","author":[{"given":"Thomas D.","family":"Horvath","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sridevi","family":"Devaraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,1]]},"reference":[{"key":"7_CR1","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.5045\/br.2020.S002","volume":"55","author":"H Kim","year":"2020","unstructured":"Kim H (2020) Treatments for children and adolescents with AML. Blood Res 55:S5\u2013S13. PMID: 32719170","journal-title":"Blood Res"},{"issue":"4","key":"7_CR2","first-page":"288","volume":"25","author":"T Ghafoor","year":"2020","unstructured":"Ghafoor T, Ahmed S, Khalil S, Farah T (2020) Optimum induction chemotherapy for pediatric acute myeloid leukemia: experience from a developing country. J Pediatr Pharmacol Ther 25(4):288\u2013294. PMID: 32461741","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"6","key":"7_CR3","first-page":"1405","volume":"10","author":"F Cacace","year":"2022","unstructured":"Cacace F, Lula R, De Novellis D, Caprioli V, D\u2019Amico MR, De Simone G, Cuccurullo R, Wierda WG, Mahadeo KM, Menna G, Tambaro FP (2022) High-risk acute myeloid leukemia: a pediatric prospective. Biomedicine 10(6):1405. PMID: 35740427","journal-title":"Biomedicine"},{"issue":"12","key":"7_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26612","volume":"64","author":"DL Johnston","year":"2017","unstructured":"Johnston DL, Alonzo TA, Gerbing RB, Aplenc R, Woods WG, Meshinchi S, Gamis AS (2017) Central nervous system disease in pediatric acute myeloid leukemia: a report from the Children\u2019s Oncology Group. Pediatr Blood Cancer 64(12):e26612. PMID: 28453910","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"7_CR5","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1002\/cncr.22562","volume":"109","author":"RM Madden","year":"2007","unstructured":"Madden RM, Pui C-H, Hughes WT, Flynn PM, Leung W (2007) Prophylaxis of Pneumocystis carinii pneumonia with atovaquone in children with leukemia. Cancer 109(8):1654\u20131658. PMID: 17345613","journal-title":"Cancer"},{"issue":"14","key":"7_CR6","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1182\/blood-2015-07-660506","volume":"128","author":"M Xiang","year":"2016","unstructured":"Xiang M, Kim H, Ho VT, Walker SR, Bar-Natan M, Anahtar M, Liu S, Toniolo PA, Kroll Y, Jones N, Giaccone ZT, Heppler LN, Ye DQ, Marineau JJ, Shaw D, Bradner JE, Blonquist T, Neuberg D, Hetz C, Stone RM, Soiffer RJ, Frank DA (2016) Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent. Blood 128(14):1845\u20131853. PMID: 27531676","journal-title":"Blood"},{"issue":"10","key":"7_CR7","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1158\/1535-7163.MCT-18-1286","volume":"18","author":"N Gupta","year":"2019","unstructured":"Gupta N, Srivastava SK (2019) Atovaquone: an antiprotozoal drug suppresses primary and resistant breast tumor growth by inhibiting HER2\/\u03b2-catenin signaling. Mol Cancer Ther 18(10):1708\u20131720. PMID 31270151","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"7_CR8","first-page":"1697","volume":"8","author":"X Gao","year":"2018","unstructured":"Gao X, Liu X, Shan W, Liu Q, Wang C, Zheng J, Yao H, Tang R, Zheng J (2018) Anti-malarial atovaquone exhibits anti-tumor effects by inducing DNA damage in hepatocellular carcinoma. Am J Cancer Res 8(9):1697\u20131711. PMID 30323964","journal-title":"Am J Cancer Res"},{"issue":"24","key":"7_CR9","doi-asserted-by":"publisher","first-page":"4215","DOI":"10.1182\/bloodadvances.2019000499","volume":"3","author":"AM Stevens","year":"2019","unstructured":"Stevens AM, Xiang M, Heppler LN, Tosic I, Jiang K, Munoz JO, Gaikwad AS, Horton TM, Long X, Narayanan P, Seashore EL, Terell MC, Rashid R, Kruger MJ, Manqubat-Medina AE, Ball ZT, Sumazin P, Walker SR, Hamada Y, Oyadomari S, Redell MS, Frank DA (2019) Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylation. Blood Adv 3(24):4215\u20134227. PMID 31856268","journal-title":"Blood Adv"},{"key":"7_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jmsacl.2022.09.004","volume":"26","author":"TD Horvath","year":"2022","unstructured":"Horvath TD, Poventud-Fuentes I, Olayinka L, James A, Haidacher SJ, Hoch KM, Stevens AM, Haag AM, Devaraj S (2022) Validation of atovaquone plasma levels by liquid chromatography-tandem mass spectrometry for therapeutic drug monitoring in pediatric patients. J Mass Spectrom Adv Clin Lab 26:23\u201327","journal-title":"J Mass Spectrom Adv Clin Lab"}],"container-title":["Methods in Molecular Biology","Clinical Applications of Mass Spectrometry in Drug Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-3541-4_7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:32:04Z","timestamp":1701390724000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-3541-4_7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"ISBN":["9781071635407","9781071635414"],"references-count":10,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-3541-4_7","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"type":"print","value":"1064-3745"},{"type":"electronic","value":"1940-6029"}],"subject":[],"published":{"date-parts":[[2023,12,1]]},"assertion":[{"value":"1 December 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}